硼替佐米联合地塞米松治疗老年多发性骨髓瘤的临床效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (0 KB) HTML (43 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Bortezomib combined with Dexamethasone(BD)in the treatment of senile multiple myeloma(MM).Methods A total of 100 elderly patients with MM who were admitted to Qilu Hospital of Shandong University and Gansu People′s Hospital from February 2012 to February 2020 were retrospectively selected as the research objects.According to different treatment regimen,they were divided into BD group(50 cases)and TD group(50 cases).The BD group was treated with Bortezomib combined with Dexamethasone regimen,while the TD group was treated with Thalidomide combined with Dexamethasone regimen.The clinical efficacy,the incidence of adverse reactions and the survival of two groups were compared.Results The total effective rate and the effective rate in the newly treated patients in BD group were higher than those in TD group,and the differences were statistically significant(P＜0.05).The increase value of hemoglobin,decrease value of serum creatinine,decrease value of serum β2 microglobulin and decrease value of plasma cell proportion in bone marrow in BD group were higher than those in TD group,and the differences were statistically significant(P＜0.05).After 4-50 months of follow-up,the survival time and survival rate in BD group were higher than those in TD group,and the differences were statistically significant(P＜0.05).The incidence of fatigue,peripheral neuropathy and myelosuppression in BD group were higher than those in TD group,and the incidence of constipation,rash,drowsiness,dizziness and deep vein thrombosis were lower than those in TD group,the differences were statistically significant(P＜0.05).There were no significant differences in the incidence of abdominal pain,diarrhea and herpes zoster between the two groups(P＞0.05).Conclusion The efficacy of BD in the elderly patients with MM is significant,and the safety is high,which is worthy of clinical promotion.

Key words： Multiple myeloma Bortezomib Dexamethasone Curative effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MI Hong-yan
	YANG Qiu-an
	SUN Yan-qing

Cite this article:

MI Hong-yan,YANG Qiu-an,SUN Yan-qing. Clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly patients with multiple myeloma[J]. 中国当代医药, 2021, 28(13): 12-16.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I13/12

[1]	陈园园，李英华，王东梅，等.低剂量硼替佐米为主的三联化疗在老年多发性骨髓瘤的疗效分析[J].中国实验血液学杂志，2020，28（2）：535-539.
[2]	陈丽娟.前言——重视老年人多发性骨髓瘤的诊治[J].实用老年医学，2013，27（9）：707.
[3]	王传芹.沙利度胺联合地塞米松或VAD 方案治疗老年多发性骨髓瘤效果及安全性分析[J].现代医学，2019，47（12）：1500-1502.
[4]	辛鹏亮，林宏峻，许文前，等.不同剂量地塞米松联合硼替佐米治疗老年多发性骨髓瘤的疗效和安全性对比分析[J].海峡药学，2020，32（4）：116-118.
[5]	刘仁同.硼替佐米联合地塞米松对老年多发性骨髓瘤患者基质细胞衍生因子-1、趋化因子受体4 表达及微血管密度的影响[J].中国老年学杂志，2020，40（3）：529-532.
[6]	Durie BG，Harousseau JL，Miguel JS，et al.International uniform response criteria for multiple myeloma[J].Leukemia，2006，20（9）：1467-1473.
[7]	路瑾.多发性骨髓瘤诊断标准的变迁及其对治疗的影响[J].中国肿瘤临床，2014，41（13）：819-822.
[8]	王得印，郝云良，肖萌，等.多发性骨髓瘤流行病学及病因分析[J].国际流行病学传染病学杂志，2018，45（4）:277-280.
[9]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[10]	余为旺.硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效分析[J].当代医学，2020，26（35）：149-151.
[11]	屈慧丽.硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效观察[J].中国医药指南，2019，17（9）：54-55.
[12]	Mateos MV，Miguel JF.Management of multiple myeloma in the newly diagnosed patient[J].Hematology Am Soc Hematol Educ Program，2017，2017（2）：498-507.
[13]	史月，薛慧，高峰，等.多发性骨髓瘤硼替佐米治疗后以肠梗阻为首发症状的周围神经病变2 例[J].临床肿瘤学杂志，2020，25（4）：378-380.
[14]	杨园园，魏仕梦，邹吉甜，等.新型蛋白酶体抑制剂伊沙佐米对多发性骨髓瘤的研究进展[J].沈阳药科大学学报，2020，37（12）：1138-1143.
[15]	邓书会，安刚，邱录贵.多发性骨髓瘤的新药研发与治疗现状[J].中国肿瘤临床，2020，47（22）：1135-1139.
[16]	杨瑛，佘笑梅，丘立丹，等.以硼替佐米为基础的化疗治疗多发性骨髓瘤的疗效与安全性[J].癌症进展，2020，18（21）：2228-2230.
[19]	张文静.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤的临床疗效评价[J].医学食疗与健康，2020，18（22）：28，57.
[17]	Van Cutsem E，Nowack IM，Lang I，et al.Randomized phase Ⅲstudy of irinotecan and 5-Fu/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer（mCRC）：The CRYSTAL trial[J].J Orthop Res，2007，18（2）：307-312.
[18]	Roccaro AM，Hideshima T，Raje N，et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood，2004，104（11）：4903-4910.
[20]	宋岭，曹波，安博文，等.不同剂量硼替佐米对多发性骨髓瘤患者临床疗效的差异性研究[J].实用癌症杂志，2019，34（1）：168-170.
[21]	符美华.硼替佐米联合地塞米松治疗多发性骨髓瘤的临床分析[J].中外医疗，2019，38（20）：92-94.
[22]	梁燕辉，沈孝春.不同部位皮下注射硼替佐米联合治疗方案在初治不适合移植的多发性骨髓瘤患者中的安全性分析探究[J].中国医药科学，2020，10（24）：18-22.
[23]	范利平.硼替佐米联合地塞米松对老年多发性骨髓瘤患者免疫功能的影响[J].实用中西医结合临床，2020，20（4）：53-54.
[24]	翁翔，陈丽，章敬成，等.改良硼替佐米联合地塞米松治疗初发多发性骨髓瘤的疗效及安全性[J].中国现代医生，2019，57（25）：8-13.
[25]	金英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息，2020，33（6）：146-147.
[26]	杨学东.地塞米松+硼替佐米治疗老年多发性骨髓瘤的临床研究[J].临床医药文献电子杂志，2019，6（85）：156-157.